Terms: = Prostate cancer AND PDGFRB, JTK12, 5159, P09619, ENSG00000113721, PDGF-R-beta, PDGFR1, CD140B, PDGFR, CD140b AND Prognosis
5 results:
1. Neuropilin-1 is over-expressed in claudin-low breast cancer and promotes tumor progression through acquisition of stem cell characteristics and RAS/MAPK pathway activation.
Tang YH; Rockstroh A; Sokolowski KA; Lynam LR; Lehman M; Thompson EW; Gregory PA; Nelson CC; Volpert M; Hollier BG
Breast Cancer Res; 2022 Jan; 24(1):8. PubMed ID: 35078508
[TBL] [Abstract] [Full Text] [Related]
2. PDGF-AA mediates mesenchymal stromal cell chemotaxis to the head and neck squamous cell carcinoma tumor microenvironment.
Watts TL; Cui R; Szaniszlo P; Resto VA; Powell DW; Pinchuk IV
J Transl Med; 2016 Dec; 14(1):337. PubMed ID: 27931212
[TBL] [Abstract] [Full Text] [Related]
3. PDGF receptors in tumor biology: prognostic and predictive potential.
Paulsson J; Ehnman M; Östman A
Future Oncol; 2014; 10(9):1695-708. PubMed ID: 25145436
[TBL] [Abstract] [Full Text] [Related]
4. Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer.
Brooks C; Sheu T; Bridges K; Mason K; Kuban D; Mathew P; Meyn R
Radiat Oncol; 2012 Sep; 7():154. PubMed ID: 22967802
[TBL] [Abstract] [Full Text] [Related]
5. Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients.
Castellano D; González-Larriba JL; Antón-Aparicio LM; Cassinello J; Grande E; Esteban E; Sepúlveda J
Expert Opin Pharmacother; 2011 Nov; 12(16):2433-9. PubMed ID: 21671835
[TBL] [Abstract] [Full Text] [Related]
